Altruist Biologics, a wholly owned subsidiary of Innovent Biologics, is a reliable biologics contract development and manufacturing organization (CDMO), providing accessible solutions to help turn breakthrough innovations into viable, life-saving therapies for patients worldwide. Altruist leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion and recombinant proteins, and bioconjugates including antibody drug conjugates (ADCs). The company offers comprehensive services, ranging from cell line development, to process and analytical method development, and through to clinical and commercial manufacturing.

Altruist offers a total 60,000-liter capacity at its Suzhou site, meeting the GMP requirements of the FDA, EMA, NMPA, and PMDA, and commenced partial operations at the new Hangzhou site with the completion of four 20,000-liter bioreactors, the first and largest of its kind in China. The Hangzhou site will hold a total capacity of 172,000 liters upon completion. The company also provides fully integrated CMC development across all ADC components – antibodies, linkers, and payloads – along with bioconjugation and sterile fill-finish capabilities.

Guided by its mission to provide a path forward for every molecule, Altruist continues to invest in new capabilities and technologies to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality products, as well as making sustainable business decisions for the betterment of global health. Further information can be found at www.altruistbio.com